CN109069643A - 药物组合物 - Google Patents

药物组合物 Download PDF

Info

Publication number
CN109069643A
CN109069643A CN201780028404.3A CN201780028404A CN109069643A CN 109069643 A CN109069643 A CN 109069643A CN 201780028404 A CN201780028404 A CN 201780028404A CN 109069643 A CN109069643 A CN 109069643A
Authority
CN
China
Prior art keywords
antibody
pharmaceutical composition
sucrose
seq
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780028404.3A
Other languages
English (en)
Chinese (zh)
Inventor
A·J·亚特斯
J·I·马斯安特
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Biopharma SRL
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56320265&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN109069643(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of CN109069643A publication Critical patent/CN109069643A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39566—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against immunoglobulins, e.g. anti-idiotypic antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
CN201780028404.3A 2016-05-12 2017-05-11 药物组合物 Pending CN109069643A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1608323.0 2016-05-12
GBGB1608323.0A GB201608323D0 (en) 2016-05-12 2016-05-12 Pharmaceutical compositions
PCT/EP2017/061261 WO2017194646A1 (en) 2016-05-12 2017-05-11 Pharmaceutical composition

Publications (1)

Publication Number Publication Date
CN109069643A true CN109069643A (zh) 2018-12-21

Family

ID=56320265

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780028404.3A Pending CN109069643A (zh) 2016-05-12 2017-05-11 药物组合物

Country Status (18)

Country Link
US (1) US11407835B2 (enExample)
EP (1) EP3454899B1 (enExample)
JP (1) JP7126454B2 (enExample)
KR (1) KR102436694B1 (enExample)
CN (1) CN109069643A (enExample)
AR (1) AR108449A1 (enExample)
AU (1) AU2017264553A1 (enExample)
BR (1) BR112018072264A2 (enExample)
CA (1) CA3022124A1 (enExample)
CL (1) CL2018003178A1 (enExample)
CO (1) CO2018011733A2 (enExample)
EA (1) EA201892446A1 (enExample)
ES (1) ES2977545T3 (enExample)
GB (1) GB201608323D0 (enExample)
IL (1) IL262654A (enExample)
MX (1) MX2018013215A (enExample)
SG (1) SG11201809229VA (enExample)
WO (1) WO2017194646A1 (enExample)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115484931A (zh) * 2020-03-11 2022-12-16 西莱克塔生物科技公司 与合成纳米载体相关的方法和组合物
CN115776879A (zh) * 2020-06-29 2023-03-10 韩兀生物制药股份有限公司 抗fcrn抗体制剂
US12194078B2 (en) 2017-03-11 2025-01-14 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物
US12472167B2 (en) 2013-05-03 2025-11-18 Cartesian Therapeutics, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI703158B (zh) 2015-09-18 2020-09-01 美商希佛隆公司 特異性結合tl1a之抗體
EP3824906A1 (en) 2016-12-21 2021-05-26 Amgen Inc. Anti-tnf alpha antibody formulations
US11603407B2 (en) 2017-04-06 2023-03-14 Regeneron Pharmaceuticals, Inc. Stable antibody formulation
GB201708655D0 (en) * 2017-05-31 2017-07-12 Ucb Biopharma Sprl Cell culture methods
BR112020019065A2 (pt) * 2018-03-23 2020-12-29 AbbVie Deutschland GmbH & Co. KG Formulações de anticorpo anti-tau aquosas estáveis
PE20212185A1 (es) 2019-02-18 2021-11-11 Lilly Co Eli Formulacion de anticuerpos terapeuticos
EP4337257A1 (en) * 2021-05-12 2024-03-20 AnaptysBio, Inc. Antibody composition
PE20241936A1 (es) 2021-12-01 2024-09-24 UCB Biopharma SRL Formulaciones que comprenden fab-peg
WO2023224112A1 (ja) * 2022-05-20 2023-11-23 株式会社ダイセル 液状医薬組成物
AU2023281650A1 (en) 2022-05-30 2024-10-17 Hanall Biopharma Co., Ltd. Anti-fcrn antibody or antigen binding fragment thereof with improved stability
CN115708810A (zh) * 2022-11-03 2023-02-24 浙江新码生物医药有限公司 含有抗cd70-药物偶联物的冻干组合物、冻干制剂及其制备方法和用途
JP2026508415A (ja) * 2023-03-08 2026-03-10 イムノバント サイエンシズ ゲーエムベーハー ポリソルベート賦形剤を含む高濃度タンパク質製剤およびその製造方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
CN101489587A (zh) * 2006-05-12 2009-07-22 伯哈拉特生物技术国际有限公司 一种可用作疫苗的组合物
CN101939338A (zh) * 2008-02-07 2011-01-05 默沙东公司 1b20 pcsk9拮抗剂
CN104364265A (zh) * 2012-05-14 2015-02-18 Ucb医药有限公司 抗FcRn抗体

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE454137T1 (de) * 2001-07-25 2010-01-15 Facet Biotech Corp Stabile lyophilisierte pharmazeutische formulierung des igg-antikörpers daclizumab
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
AR070316A1 (es) * 2008-02-07 2010-03-31 Merck & Co Inc Antagonistas de pcsk9 (proproteina subtilisina-kexina tipo 9)
MX2011013722A (es) * 2009-06-18 2012-05-08 Wyeth Llc Formulaciones liofilizadas para inmunofarmaceuticos modulares pequeños.
US9072668B2 (en) 2010-03-09 2015-07-07 Janssen Biotech, Inc. Non-aqueous high concentration reduced viscosity suspension formulations of antibodies
US8788028B2 (en) 2010-07-28 2014-07-22 Medtronic, Inc. Parasympathetic stimulation to enhance tachyarrhythmia detection
WO2012076670A2 (en) 2010-12-10 2012-06-14 Novartis Ag Antibody formulation
WO2012135408A1 (en) 2011-03-31 2012-10-04 Merck Sharp & Dohme Corp. Stable formulations of antibodies to human programmed death receptor pd-1 and related treatments
JOP20200043A1 (ar) 2011-05-10 2017-06-16 Amgen Inc طرق معالجة أو منع الاضطرابات المختصة بالكوليسترول
US9592289B2 (en) * 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
JP6265970B2 (ja) 2012-03-26 2018-01-24 サノフイ 安定なＩｇＧ４に基づく結合剤の製剤
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
WO2014093206A1 (en) 2012-12-13 2014-06-19 Merck Sharp & Dohme Corp. Lyophilized spherical pellets of anti-il-23 antibodies
WO2015121318A1 (en) * 2014-02-12 2015-08-20 Sanofi Anti-il-4/anti-il-13 bispecific antibody/polyglutamate formulations
US20170247460A1 (en) 2014-10-18 2017-08-31 Pfizer Inc. Anti-il-7r antibody compositions
GB201508180D0 (en) 2015-05-13 2015-06-24 Ucb Biopharma Sprl Antibodies

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101124245A (zh) * 2003-11-12 2008-02-13 比奥根艾迪克Ma公司 新生儿Fc受体(FcRn)-结合多肽变体、二聚体Fc结合蛋白及其相关方法
CN101489587A (zh) * 2006-05-12 2009-07-22 伯哈拉特生物技术国际有限公司 一种可用作疫苗的组合物
CN101939338A (zh) * 2008-02-07 2011-01-05 默沙东公司 1b20 pcsk9拮抗剂
CN104364265A (zh) * 2012-05-14 2015-02-18 Ucb医药有限公司 抗FcRn抗体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
SALMAN MUZAMMIL等: "FcRn binding is not sufficient for achieving systemic therapeutic levels of immunoglobulin G after oral delivery of enteric-coated capsules in cynomolgus macaques", 《PHARMA RES PER》 *

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12472167B2 (en) 2013-05-03 2025-11-18 Cartesian Therapeutics, Inc. Methods providing a therapeutic macromolecule and synthetic nanocarriers comprising immunosuppressant locally and concomitantly to reduce both Type 1 and Type IV hypersensitivity
US12508249B2 (en) 2013-05-03 2025-12-30 Cartesian Therapeutics Inc. Methods related to administering immunosuppressants and non-allergenic antigens to reduce or prevent anaphylaxis
US12194078B2 (en) 2017-03-11 2025-01-14 Cartesian Therapeutics, Inc. Methods and compositions related to combined treatment with anti-inflammatories and synthetic nanocarriers comprising an immunosuppressant
US12553041B2 (en) 2019-06-04 2026-02-17 Cartesian Therapeutics Inc. Formulations and doses of pegylated uricase
CN115484931A (zh) * 2020-03-11 2022-12-16 西莱克塔生物科技公司 与合成纳米载体相关的方法和组合物
CN115776879A (zh) * 2020-06-29 2023-03-10 韩兀生物制药股份有限公司 抗fcrn抗体制剂
WO2025056011A1 (zh) * 2023-09-13 2025-03-20 正大天晴药业集团股份有限公司 包含抗pd-1抗体和第二抗体的药物组合物

Also Published As

Publication number Publication date
CO2018011733A2 (es) 2019-02-08
IL262654A (en) 2018-12-31
US20200048346A1 (en) 2020-02-13
WO2017194646A1 (en) 2017-11-16
CL2018003178A1 (es) 2019-02-01
RU2018141591A (ru) 2020-06-15
SG11201809229VA (en) 2018-11-29
MX2018013215A (es) 2019-02-21
US11407835B2 (en) 2022-08-09
ES2977545T3 (es) 2024-08-26
CA3022124A1 (en) 2017-11-16
GB201608323D0 (en) 2016-06-29
EP3454899C0 (en) 2024-03-20
BR112018072264A2 (pt) 2019-02-12
KR102436694B1 (ko) 2022-08-25
KR20190008320A (ko) 2019-01-23
RU2018141591A3 (enExample) 2021-01-13
EA201892446A1 (ru) 2019-04-30
EP3454899B1 (en) 2024-03-20
JP2019514998A (ja) 2019-06-06
JP7126454B2 (ja) 2022-08-26
AU2017264553A1 (en) 2018-12-13
AR108449A1 (es) 2018-08-22
EP3454899A1 (en) 2019-03-20

Similar Documents

Publication Publication Date Title
EP3454899B1 (en) Pharmaceutical composition
US20230355758A1 (en) Pharmaceutical Formulations
JP6784683B2 (ja) 医薬製剤
JP6339578B2 (ja) Ｇｍ−ｃｓｆ中和化合物を含む凍結乾燥製剤
CN109414426A (zh) 使用精氨酸耗竭剂的组合癌症免疫疗法
US20200390705A1 (en) Method for reducing the reconstitution time of spray-dried protein formulations
RU2775944C2 (ru) Фармацевтическая композиция
CN116688115B (zh) 一种PD-L1/TGF-β双功能融合蛋白制剂及其用途
TW202317184A (zh) 用於治療異位性皮膚炎和相關障礙之方法
EA041921B1 (ru) Фармацевтическая композиция
CN116763917A (zh) 一种稳定的抗人il15/pd-l1双功能融合蛋白制剂

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information

Address after: Brussels

Applicant after: UCB biopharmaceutical Co.,Ltd.

Address before: Brussels

Applicant before: UCB BIOPHARMA SPRL

CB02 Change of applicant information